Organovo Holdings Inc.

07/16/2024 | Press release | Distributed by Public on 07/16/2024 06:24

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.